Collectively, these findings suggest that GH promotes chemoresistance in NSCLC by upregulating ABC transporter expression, while pegvisomant effectively counteracts this effect, highlighting its potential therapeutic role in sensitizing tumors to chemotherapy. Here, GH1 is linked to non-small cell lung carcinoma.